Axon Enterprise (NASDAQ:AXON) Price Target Raised to $370.00

Axon Enterprise (NASDAQ:AXON) had its target price boosted by Craig Hallum from $325.00 to $370.00 in a research note published on Tuesday morning, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

Other equities analysts also recently issued reports about the company. Argus initiated coverage on Axon Enterprise in a research report on Wednesday, March 13th. They issued a buy rating and a $380.00 price objective on the stock. StockNews.com cut Axon Enterprise from a buy rating to a hold rating in a report on Thursday, March 14th. Robert W. Baird increased their price objective on shares of Axon Enterprise from $260.00 to $300.00 and gave the company an outperform rating in a report on Thursday, February 22nd. Barclays boosted their target price on shares of Axon Enterprise from $296.00 to $308.00 and gave the stock an overweight rating in a report on Thursday, February 29th. Finally, William Blair reaffirmed an outperform rating on shares of Axon Enterprise in a research note on Wednesday, April 24th. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Axon Enterprise presently has a consensus rating of Moderate Buy and an average target price of $327.00.

Axon Enterprise Trading Down 4.6 %

Axon Enterprise stock opened at $312.73 on Tuesday. Axon Enterprise has a 12-month low of $175.37 and a 12-month high of $329.87. The firm has a market capitalization of $23.60 billion, a price-to-earnings ratio of 135.97 and a beta of 0.91. The firm has a 50 day moving average of $310.77 and a 200 day moving average of $267.13. The company has a current ratio of 3.00, a quick ratio of 2.66 and a debt-to-equity ratio of 0.42.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Monday, May 6th. The biotechnology company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.20. Axon Enterprise had a net margin of 11.14% and a return on equity of 14.11%. The firm had revenue of $460.74 million during the quarter, compared to analysts’ expectations of $441.57 million. During the same period in the prior year, the company posted $0.51 earnings per share. The company’s revenue for the quarter was up 34.3% compared to the same quarter last year. As a group, research analysts predict that Axon Enterprise will post 2.44 earnings per share for the current year.

Hedge Funds Weigh In On Axon Enterprise

A number of institutional investors and hedge funds have recently made changes to their positions in AXON. Cambridge Investment Research Advisors Inc. grew its position in Axon Enterprise by 8.9% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 7,716 shares of the biotechnology company’s stock worth $1,535,000 after acquiring an additional 630 shares in the last quarter. Mackenzie Financial Corp increased its position in shares of Axon Enterprise by 2.3% during the 3rd quarter. Mackenzie Financial Corp now owns 6,292 shares of the biotechnology company’s stock valued at $1,208,000 after purchasing an additional 141 shares during the last quarter. Advisor Partners II LLC increased its position in shares of Axon Enterprise by 3.5% during the 3rd quarter. Advisor Partners II LLC now owns 3,407 shares of the biotechnology company’s stock valued at $678,000 after purchasing an additional 115 shares during the last quarter. Park Avenue Securities LLC purchased a new stake in Axon Enterprise during the 3rd quarter valued at $828,000. Finally, TD Asset Management Inc lifted its position in Axon Enterprise by 3.0% in the third quarter. TD Asset Management Inc now owns 22,342 shares of the biotechnology company’s stock worth $4,446,000 after buying an additional 645 shares during the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.